Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer IndicationsElena Ardini, Arturo Galvani, Maria Menichincheri et al.|Molecular Cancer Therapeutics|2016Cited by 317
A catalytically silent FAAH-1 variant drives anandamide transport in neuronsJin Fu, Daniele Piomelli, Giovanni Bottegoni et al.|Nature Neuroscience|2011Cited by 170
The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibitionElena Ardini, Antonella Isacchi, Alessio Somaschini et al.|Molecular Oncology|2014Cited by 156
Effects of peripheral FAAH blockade on NTG-induced hyperalgesia—evaluation of URB937 in an animal model of migraineRosaria Greco, Cristina Tassorelli, Tiziano Bandiera et al.|Cephalalgia|2015Cited by 62
Abstract A243: Characterization of NMS-E628, a small molecule inhibitor of anaplastic lymphoma kinase with antitumor efficacy in ALK-dependent lymphoma and non-small cell lung cancer modelsElena Ardini, Arturo Galvani, Maria Menichincheri et al.|Molecular Cancer Therapeutics|2009Cited by 31